{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:13:08Z","timestamp":1794607988677,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13346-024-01732-5","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T17:02:53Z","timestamp":1730134973000},"page":"2200-2219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Topical delivery of baricitinib-impregnated nanoemulgel: a promising platform for inhibition of JAK -STAT pathway for the effective management of atopic dermatitis"],"prefix":"10.1007","volume":"15","author":[{"given":"Shweta","family":"Nene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetanjali","family":"Devabattula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Vambhurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamatham Pushpa","family":"Tryphena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmendra Kumar","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandraiah","family":"Godugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-4363","authenticated-orcid":false,"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"1732_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"M Sin\u00e9ad","year":"2020","unstructured":"Sin\u00e9ad M, Langan AD, Irvine SW. Atopic dermatitis. Lancet. 2020;396:345\u201360.","journal-title":"Lancet"},{"key":"1732_CR2","doi-asserted-by":"publisher","unstructured":"Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Ann Allergy, Asthma Immunol [Internet]. 2018;120:34\u201341. http:\/\/www.embase.com\/search\/results?subaction=viewrecordfrom=exportid=L6191375730https:\/\/doi.org\/10.1016\/j.anai.2017.09.055","DOI":"10.1016\/j.anai.2017.09.055"},{"key":"1732_CR3","doi-asserted-by":"crossref","unstructured":"Stephan Weidinger, Lisa A. Beck2, Thomas Bieber3, 4 KK, Irvine and AD. Atopic dermatitis. Nat Rev Dis Prim. 2018.","DOI":"10.1038\/s41572-018-0001-z"},{"key":"1732_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"1732_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1080\/09546634.2020.1839008","volume":"33","author":"K Reich","year":"2022","unstructured":"Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2022;33:1521\u201330.","journal-title":"J Dermatolog Treat"},{"key":"1732_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/14656566.2020.1739268","volume":"21","author":"JT Mendes","year":"2020","unstructured":"Mendes JT, Balogh EA, Strowd LC, Feldman SR. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis. Expert Opin Pharmacother. 2020;21:1027\u201333.","journal-title":"Expert Opin Pharmacother"},{"key":"1732_CR7","doi-asserted-by":"crossref","unstructured":"Garr\u00f3s N, Bustos-Salgados P, Dom\u00e8nech \u00d2, Rodr\u00edguez-Lagunas MJ, Beirampour N, Mohammadi-Meyabadi R et al. Baricitinib Lipid-Based Nanosystems as a Topical Alternative for atopic Dermatitis treatment. Pharmaceuticals. 2023;16.","DOI":"10.3390\/ph16060894"},{"key":"1732_CR8","doi-asserted-by":"crossref","unstructured":"G\u00fcng\u00f6r S, Kahraman E. Nanocarriers mediated cutaneous drug delivery. Eur J Pharm Sci. 2021;158.","DOI":"10.1016\/j.ejps.2020.105638"},{"key":"1732_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jconrel.2017.11.049","volume":"270","author":"VK Rai","year":"2018","unstructured":"Rai VK, Mishra N, Yadav KS, Yadav NP. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: Formulation development, stability issues, basic considerations and applications. J Control Release. 2018;270:203\u201325.","journal-title":"J Control Release"},{"key":"1732_CR10","doi-asserted-by":"crossref","unstructured":"Nene S, Devabattula G, Vambhurkar G, Tryphena KP, Singh PK, Khatri DK et al. High mobility group box 1 cytokine targeted topical delivery of resveratrol embedded nanoemulgel for the management of atopic dermatitis. Drug Deliv Transl Res. 2024.","DOI":"10.1007\/s13346-024-01565-2"},{"key":"1732_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejpb.2006.10.014","volume":"66","author":"S Shafiq","year":"2007","unstructured":"Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66:227\u201343.","journal-title":"Eur J Pharm Biopharm"},{"key":"1732_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jsps.2019.01.012","volume":"27","author":"MJ Ansari","year":"2019","unstructured":"Ansari MJ, Alshahrani SM. Nano-encapsulation and characterization of baricitinib using poly-lactic-glycolic acid co-polymer. Saudi Pharm J. 2019;27:491\u2013501.","journal-title":"Saudi Pharm J"},{"key":"1732_CR13","doi-asserted-by":"publisher","first-page":"9783","DOI":"10.2147\/IJN.S278688","volume":"15","author":"S Ahmed","year":"2020","unstructured":"Ahmed S, Kassem MA, Sayed S. Bilosomes as promising nanovesicular carriers for improved transdermal delivery: construction, in vitro optimization, ex vivo permeation and in vivo evaluation. Int J Nanomed. 2020;15:9783\u201398.","journal-title":"Int J Nanomed"},{"key":"1732_CR14","doi-asserted-by":"crossref","unstructured":"Pandey SS, Shah KM, Maulvi FA, Desai DT, Gupta AR, Joshi SV et al. Topical delivery of cyclosporine loaded tailored niosomal nanocarriers for improved skin penetration and deposition in psoriasis: optimization, ex vivo and animal studies. J Drug Deliv Sci Technol. 2021;63.","DOI":"10.1016\/j.jddst.2021.102441"},{"key":"1732_CR15","doi-asserted-by":"crossref","unstructured":"Parmar PK, Sharma N, Wasil Kabeer S, Rohit A, Bansal AK. Nanocrystal-based gel of apremilast ameliorates imiquimod-induced psoriasis by suppressing inflammatory responses. Int J Pharm. 2022;622.","DOI":"10.1016\/j.ijpharm.2022.121873"},{"key":"1732_CR16","doi-asserted-by":"crossref","unstructured":"Jang S, Ohn J, Kim JW, Kang SM, Jeon D, Heo CY et al. Caffeoyl\u2013pro\u2013his amide relieve DNCB-Induced Atopic Dermatitis-Like phenotypes in BALB\/c mice. Sci Rep. 2020;10.","DOI":"10.1038\/s41598-020-65502-2"},{"key":"1732_CR17","doi-asserted-by":"crossref","unstructured":"Jin W, Huang W, Chen L, Jin M, Wang Q, Gao Z et al. Topical application of JAK1\/JAK2 inhibitor momelotinib exhibits significant anti-inflammatory responses in DNCB-induced atopic dermatitis model mice. Int J Mol Sci. 2018;19.","DOI":"10.3390\/ijms19123973"},{"key":"1732_CR18","doi-asserted-by":"crossref","unstructured":"Gangadevi V, Thatikonda S, Pooladanda V, Devabattula G, Godugu C. Selenium nanoparticles produce a beneficial effect in psoriasis by reducing epidermal hyperproliferation and inflammation. J Nanobiotechnol. 2021;19.","DOI":"10.1186\/s12951-021-00842-3"},{"key":"1732_CR19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.jid.2018.01.036","volume":"138","author":"N Vandeghinste","year":"2018","unstructured":"Vandeghinste N, Klattig J, Jagerschmidt C, Lavazais S, Marsais F, Haas JD, et al. Neutralization of IL-17\u00a0C reduces skin inflammation in mouse models of Psoriasis and atopic dermatitis. J Invest Dermatol. 2018;138:1555\u201363.","journal-title":"J Invest Dermatol"},{"key":"1732_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-60761-849-2_4","volume":"691","author":"M Slaoui","year":"2011","unstructured":"Slaoui M, Fiette L. Histopathology procedures: from tissue sampling to histopathological evaluation. Methods Mol Biol. 2011;691:69\u201382.","journal-title":"Methods Mol Biol"},{"key":"1732_CR21","doi-asserted-by":"crossref","unstructured":"Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10.","DOI":"10.3390\/pharmaceutics10020057"},{"key":"1732_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jps.21817","volume":"99","author":"B Baroli","year":"2010","unstructured":"Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci. 2010;99:21\u201350.","journal-title":"J Pharm Sci"},{"key":"1732_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.15171\/apb.2016.06","volume":"6","author":"Z Mardhiah Adib","year":"2016","unstructured":"Mardhiah Adib Z, Ghanbarzadeh S, Kouhsoltani M, Yari Khosroshahi A, Hamishehkar H. The Effect of particle size on the deposition of solid lipid nanoparticles in different skin layers: a histological study. Adv Pharm Bull. 2016;6:31\u20136.","journal-title":"Adv Pharm Bull"},{"key":"1732_CR24","doi-asserted-by":"crossref","unstructured":"Abd-Rabou AA, Edris AE. Cytotoxic, apoptotic, and genetic evaluations of Nigella sativa essential oil nanoemulsion against human hepatocellular carcinoma cell lines. Cancer Nanotechnol. 2021;12.","DOI":"10.1186\/s12645-021-00101-y"},{"key":"1732_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijpharm.2019.03.042","volume":"562","author":"S Jain","year":"2019","unstructured":"Jain S, Addan R, Kushwah V, Harde H, Mahajan RR. Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded nanoformulations. Int J Pharm. 2019;562:96\u2013104.","journal-title":"Int J Pharm"},{"key":"1732_CR26","doi-asserted-by":"crossref","unstructured":"Hasan N, Imran M, Nadeem M, Jain D, Haider K, Moshahid Alam Rizvi M et al. Formulation and development of novel lipid-based combinatorial advanced nanoformulation for effective treatment of non-melanoma skin cancer. Int J Pharm. 2023;632.","DOI":"10.1016\/j.ijpharm.2022.122580"},{"key":"1732_CR27","doi-asserted-by":"crossref","unstructured":"Liu X, Xu L, Liu X, Wang Y, Zhao Y, Kang Q et al. Combination of essential oil from Zanthoxylum Bungeanum Maxim. And a microemulsion system: permeation enhancement effect on drugs with different lipophilicity and its mechanism. J Drug Deliv Sci Technol. 2020;55.","DOI":"10.1016\/j.jddst.2019.101309"},{"key":"1732_CR28","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1021\/acsapm.1c00021","volume":"3","author":"EVR Campos","year":"2021","unstructured":"Campos EVR, Proen\u00e7a PLF, Costa TG, De Da R, Hedtrich S, Fraceto LF, et al. Hydrogels containing budesonide-loaded nanoparticles to facilitate percutaneous absorption for atopic Dermatitis Treatment Applications. ACS Appl Polym Mater. 2021;3:4436\u201349.","journal-title":"ACS Appl Polym Mater"},{"key":"1732_CR29","doi-asserted-by":"crossref","unstructured":"Atmakuri S, Nene S, Jain H, Joga R, Devabattula G, Godugu C et al. Topical delivery of tofacitinib citrate loaded novel nanoemulgel for the management of 2,4-Dichlorodinitrobenzene induced atopic dermatitis in mice model. J Drug Deliv Sci Technol. 2023;80.","DOI":"10.1016\/j.jddst.2022.104145"},{"key":"1732_CR30","doi-asserted-by":"crossref","unstructured":"Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020;9.","DOI":"10.7573\/dic.2020-8-5"},{"key":"1732_CR31","doi-asserted-by":"crossref","unstructured":"De Ara\u00fajo Lopes A, Da Fonseca FN, Rocha TM, De Freitas LB, Ara\u00fajo EVO, Wong DVT et al. Eugenol as a promising molecule for the treatment of dermatitis: Antioxidant and anti-inflammatory activities and its nanoformulation. Oxid Med Cell Longev. 2018;2018.","DOI":"10.1155\/2018\/8194849"},{"key":"1732_CR32","doi-asserted-by":"crossref","unstructured":"Brandt B. E. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;02.","DOI":"10.4172\/2155-9899.1000110"},{"key":"1732_CR33","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1067\/mai.2000.106484","volume":"105","author":"DYM Leung","year":"2000","unstructured":"Leung DYM. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol. 2000;105:860\u201376.","journal-title":"J Allergy Clin Immunol"},{"key":"1732_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.15570\/actaapa.2022.3","volume":"31","author":"M Alsabbagh","year":"2022","unstructured":"Alsabbagh M, Ismaeel A. The role of cytokines in atopic dermatitis: a breakthrough in immunopathogenesis and treatment. Acta Dermatovenerologica Alpina Pannonica Adriat. 2022;31:13\u201331.","journal-title":"Acta Dermatovenerologica Alpina Pannonica Adriat"},{"key":"1732_CR35","doi-asserted-by":"crossref","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. JAK\u2013STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13.","DOI":"10.3389\/fimmu.2022.1068260"},{"key":"1732_CR36","doi-asserted-by":"publisher","first-page":"e24137","DOI":"10.4161\/jkst.24137","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. Jak-Stat. 2013;2:e24137.","journal-title":"Jak-Stat"},{"key":"1732_CR37","doi-asserted-by":"crossref","unstructured":"Hu X, li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6.","DOI":"10.1038\/s41392-021-00791-1"},{"key":"1732_CR38","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.jaad.2017.12.019","volume":"78","author":"DG Cotter","year":"2018","unstructured":"Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78:S53\u201362.","journal-title":"J Am Acad Dermatol"},{"key":"1732_CR39","doi-asserted-by":"crossref","unstructured":"Kubo S, Nakayamada S, Sakata K, Kitanaga Y, Ma X, Lee S et al. Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system. Front Immunol. 2018;9.","DOI":"10.3389\/fimmu.2018.01510"},{"key":"1732_CR40","doi-asserted-by":"crossref","unstructured":"Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in Dermatology. Front Immunol. 2019;10.","DOI":"10.3389\/fimmu.2019.02847"},{"key":"1732_CR41","doi-asserted-by":"crossref","unstructured":"Espinoza LC, Vera-Garc\u00eda R, Silva-Abreu M, Dom\u00e8nech \u00d2, Badia J, Rodr\u00edguez-Lagunas MJ et al. Topical pioglitazone nanoformulation for the treatment of atopic dermatitis: design, characterization and efficacy in hairless mouse model. Pharmaceutics. 2020;12.","DOI":"10.3390\/pharmaceutics12030255"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01732-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01732-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01732-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T12:52:29Z","timestamp":1745844749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01732-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01732-5","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"10 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The required number of male BALB\/c mice with average weight ranging from 25 to 30\u00a0g were procured from Vyas Labs, Hyderabad, India. Before one week of experimentation, animals were acclimatized to standard laboratory conditions and given free access to fresh water and a normal pellet diet. The experimental animal protocol with protocol number NIP\/04\/2022\/PE\/467 was approved by the Institutional Animal Ethics Committee (IAEC) and the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India on 20th April, 2022. The animal experiments were performed as per the guidelines mentioned by Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interest to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}